Diana Bernstein


Diana is an associate at Flagship Pioneering, working as part of a team of entrepreneurial scientists to conceive, create, resource and develop the next generation of Flagship’s first-in-category ventures. She joined the firm after completing the Flagship VentureLabs Fellows program. Diana brings together business acumen with expertise in pharmacology, epigenetics and gene delivery systems.

Before joining Flagship, Diana served as project manager at Sigma-Tau Pharmaceuticals, Inc., where she defined and managed programs to drive drug development for rare diseases. At Sigma-Tau, she developed and led the commercial launch plan for CYSTARAN™, an ophthalmic treatment for cystinosis, and played a significant role in the integration of the acquisition of Enzon Pharmaceuticals’ specialty pharmaceuticals business. Diana also worked as a business development analyst at Sigma-Tau and as an associate at PricewaterhouseCoopers Health Industries Advisory Practice, where she focused on financial performance of hospital facilities and e-marketing at global biotechnology companies.

Diana received her Ph.D. in pharmacology from the University of Pennsylvania Perelman School of Medicine, where she completed her doctoral dissertation research on epigenetic editing and diabetes in the lab of Klaus Kaestner, Ph.D., which resulted in the filing of related patents. She also completed select Wharton and industry coursework and took a managerial position in the Penn Biotech Group consulting organization. Diana earned her B.S. in finance and B.S. in cell biology and genetics from the University of Maryland, where she graduated with honors from the Hinman CEOs entrepreneurship program.

Diana Bernstein